Phase I/II study of CT-2103 (Xyotax) in patients with recurrent ovarian cancer

被引：0
|
作者：
Sabbatini, P
Brown, J
Peters, WA
Jacobs, A
Mehdi, A
Crozier, MA
Rivkin, S
Bolton, MG
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, New York, NY 10021 USA
[2] Gynecol Oncol Associates, Dept Med Oncol, Newport Beach, CA USA
[3] Pacific Gynecol Specialists, Dept Med Oncol, Seattle, WA USA
[4] Virginia Mason Med Ctr, Dept Med Oncol, Seattle, WA 98101 USA
[5] Stockton Hematol Oncol Med Grp, Dept Med Oncol, Stockton, CA USA
[6] SW Reg Canc Ctr, Dept Med Oncol, Austin, TX USA
[7] Swedish Med Ctr & Tumor Inst, Dept Med Oncol, Seattle, WA USA
[8] Cell Therapeut Inc, Clin Dev, Seattle, WA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
430
引用
收藏
页码：S130 / S130
页数：1
相关论文
共 50 条
  • [1] Phase I study of Xyotax (CT-2103) and cisplatin in patients with solid tumors: preliminary data
    Kudelka, A
    Skubitz, K
    Kavanagh, J
    Garzone, PG
    Bolton, MG
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S132 - S132
  • [2] Phase I study of Xyotax (CT-2103) and carboplatin in patients with solid tumors: preliminary data
    Neumanitis, J
    Garzone, P
    Bolton, MG
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S132 - S132
  • [3] Phase II study of Xyotax (CT-2103) in patients with colorectal cancer having recurrent disease after treatment with a 5-fluorouracil-containing regimen
    Schulz, J
    Burris, H
    Redfern, C
    Warner, M
    Paradise, C
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S132 - S132
  • [4] Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
    Sabbatini, P
    Aghajanian, C
    Dizon, D
    Anderson, S
    Dupont, J
    Brown, JV
    Peters, WA
    Jacobs, A
    Mehdi, A
    Rivkin, S
    Eisenfeld, AJ
    Spriggs, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (22) : 4523 - 4531
  • [5] Paclitaxel poliglumex (XYOTAX™, CT-2103):: A macromolecular taxane
    Singer, JW
    JOURNAL OF CONTROLLED RELEASE, 2005, 109 (1-3) : 120 - 126
  • [6] Early findings in a phase I study of PG-paclitaxel (CT-2103) in recurrent ovarian or peritoneal cancer.
    Sabbatini, P
    Soignet, S
    Aghajanian, C
    Hensley, M
    Pezzulli, S
    Oflaherty, C
    Wengrow, A
    Funt, S
    Chi, D
    Odujinrin, O
    Warner, M
    Spriggs, D
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3748S - 3748S
  • [7] Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane
    Singer, JW
    Shaffer, S
    Baker, B
    Bernareggi, A
    Stromatt, S
    Nienstedt, D
    Besman, M
    ANTI-CANCER DRUGS, 2005, 16 (03) : 243 - 254
  • [8] Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors
    Maria Luisa Veronese
    Keith Flaherty
    Amy Kramer
    Barbara A. Konkle
    Mark Morgan
    James P. Stevenson
    Peter J. O’Dwyer
    Cancer Chemotherapy and Pharmacology, 2005, 55 : 497 - 501
  • [9] Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors
    Veronese, ML
    Flaherty, K
    Kramer, A
    Konkle, BA
    Morgan, M
    Stevenson, JP
    O'Dwyer, PJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 55 (05) : 497 - 501
  • [10] Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors
    Nemunaitis, J
    Cunningham, C
    Senzer, N
    Gray, M
    Oldham, F
    Pippen, J
    Mennel, R
    Eisenfeld, A
    CANCER INVESTIGATION, 2005, 23 (08) : 671 - 676
12345